Microneedle Solutions raises €86K Seed round
30 January 2024· Leeds, United Kingdom· health, biotech, materials, b2b, deep_hardware
MNS aimed to use this funding to finalize in vivo and in vitro studies, compile reliable data, and expand their IP portfolio in preparation for human trials.
Investors
LeadPioneer Group
Also participating
SFC CapitalCambridge Angels
About Microneedle Solutions
Stage
Seed
Headquarters
Leeds, United Kingdom
Founded
2022
Team Size
6–20
Sectors
healthbiotechmaterialsb2bdeep_hardware